Table 1.
Clinical characteristics and laboratory findings of the study population
| Characteristics | SCAP (n = 103) | Non-SCAP (n = 149) | p value |
|---|---|---|---|
| Age (years) | 56.14 ± 17.32 | 50 (33 - 65) | 0.007 |
| Male (n) | 73 (70.87%) | 92 (61.74%) | 0.135 |
| Past medical history | |||
| Chronic heart failure | 6 (5.82%) | 9 (6.04%) | 0.959 |
| Diabetes mellitus | 12 (11.65%) | 23 (15.44%) | 0.394 |
| Cerebrovascular disease | 17 (16.50%) | 13 (8.72%) | 0.061 |
| Chronic liver disease | 7 (6.80%) | 4 (2.68%) | 0.063 |
| COPD | 7 (6.80%) | 5 (3.35%) | 0.208 |
| Smoking | 46 (44.66%) | 76 (51.01%) | 0.274 |
| Antibiotic pre-treatment | 38 (36.90%) | 71 (47.65%) | 0.288 |
| Pathogen established | 50 (48.54%) | 65 (43.62%) | 0.442 |
| Chest x-ray | |||
| Bilateral lung infection | 87 (84.47%) | 44 (29.53%) | <0.001 |
| Pleural effusion | 30 (29.13%) | 7 (4.70%) | <0.001 |
| WBC (×109/L) | 10.05 (6.80‒15.21) | 7.49 (5.52‒10.79) | <0.001 |
| NE% | 84.00 (76.40‒90.70) | 74.36 (63.95‒81.68) | <0.001 |
| LY% | 8.70 (5.05‒14.20) | 16.30 (9.72‒27.05) | <0.001 |
| NLR | 10.04 (5.77‒17.99) | 4.55 (2.46‒8.40) | <0.001 |
| CRP (mg/L) | 107.10 (26.00‒189.00) | 46.16 (9.19‒108.7) | 0.001 |
| PCT (μg/L) | 0.54 (0.20‒3.43) | 0.14 (0.05‒0.64) | <0.001 |
| CURB-65 | 1 (0‒ 2) | 0 (0‒1) | <0.001 |
| PSI | 94 ± 37 | 58 (35‒72) | <0.001 |
| APACHE II score | 15 ± 6 | 8 (6‒9) | <0.001 |
| Total mortality | 19 (18.45%) | 0 (0%) | <0.001 |
| 30-day mortality | 18 (17.48) | 0 (0%) | <0.001 |
COPD chronic obstructive pulmonary disease, WBC white blood cells, NLR neutrophil/lymphocyte ratio, CRP C-reactive protein, PCT procalcitonin, CURB-65 confusion, urea, respiratory rate, blood pressure, and age ≥65 years old, PSI Pneumonia Severity Index, APACHE II Acute Physiology and Chronic Health Evaluation II